Matrix Metalloproteinases and Their Inhibitors in Kidney Scarring: Culprits or Innocents

Aimun Kamal Hussein Ahmed

The Sheffield Kidney Institute, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

(Received September 20, 2008; Accepted May 18, 2009)

The renal extracellular matrix (ECM) is in a continual state of turnover with homeostasis maintained by balancing synthesis and degradation rates. During progressive kidney scarring an imbalance occurs leading to increase ECM either by increased deposition or decreased breakdown, although a combination of the two is more likely. Increased synthesis of many ECM proteins such as collagens I, III, and IV, fibronectin and laminin contribute to this imbalance; however decreased proteolytic activity leading to accumulation of ECM components is also an important component of scarring. The matrix metalloproteinases (MMPs) system is predominantly responsible for degrading mature ECM, consisting of 24 members, with MMP’s 1, 2, 3, 8, 9, and 13 having significant renal expression. The kidney also expresses 3 Tissue inhibitors of MMPs; TIMP-1, 2, and 3. MMPs also have a role during kidney development. Several studies describe changes in ECM proteolysis and more specifically MMPs in end stage kidney disease (ESRD), although most of these are descriptive and based on enzymatic, protein or mRNA analysis of homogenates. There is no consistency in most of these studies regarding the expression of MMPs and TIMPS in experimental kidney scarring. Few of these studies have been investigated in human kidney scarring. Here is a comprehensive review of the MMPs and TIMPs literature including their action, activation, regulation, and contribution in experimental and human CKD.

Key words — matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, chronic kidney disease, kidney scarring, kidney fibrosis

INTRODUCTION

Kidney scarring is an inevitable consequence of progressive chronic kidney disease (CKD). Kidney scarring leads to end stage renal disease (ESRD), a devastating disorder which has a common histological end point to most progressive kidney diseases, such as diabetes mellitus, glomerulonephritis, focal sclerosis, chronic transplant dysfunction, etc. Kidney scarring represents a failed wound-healing process of the kidney tissue after chronic, sustained injury, with loss of resident kidney cells and their replacement by infiltrating inflammatory cells and fibrous tissue. Several cellular pathways, including mesangial and fibroblast activation as well as tubular epithelial-mesenchymal transition (EMT) have been involved in the generation of the matrix-producing cells leading to extracellular matrix (ECM) accumulation. ECM is in continuous state of turnover with a tight balance between its synthesis and degradation, during progressive kidney scarring there is imbalance with either increased deposition or decreased breakdown or a combination of both. The mechanisms behind the accumulation of ECM in progressive CKD are important from both a pathogenic perspectives, and as potential targets for therapeutic intervention. Many fibrogenic factors regulate kidney fibrotic process, as well as matrix-degrading enzymes. Interstitial recruitment of inflammatory leukocytes and myofibroblasts occurs early in kidneys developing fibrosis. Circulating monocytes are recruited by locally secreted chemoattractant molecules, facilitated by leukocyte adhesion molecules. The matrix metalloproteinases (MMPs) system is considered one of the major systems responsible for degrading accu-
mulated ECM and balancing the ECM turnover. Here is a comprehensive review of their action, activation, regulation, and their contribution in experimental and human CKD.

**THE KIDNEY ECM**

The ECM in the kidney like elsewhere in the body, a three-dimensional network of macromolecules (collagens, elastin, fibronectin, laminins and glycosaminoglycans). ECM plays an integral role in basement membrane composition, cell development, homeostasis, physiology and pathology. It functions through interaction with specific receptors that regulate many aspects of cellular behavior including growth, migration, differentiation, repair, and serves not only as a structural scaffold but also as an instructive environment for tissues and cells. The ECM transmits signals from cells to ECM and vice versa, mediating cell adhesion, proliferation, and survival. Basement membranes (BM) are important components formed of thin sheets of specialized ECM, which support epithelial cell layers. The main components of the kidney ECM are collagen types I, III, IV, and V. Other abundant ECM proteins include laminin, fibronectin, heparan sulphate proteoglycans (HSPG), and chondroitin sulphate proteoglycan. Type V is a fibrillar collagen and is found mainly in the mesangium and in the interstitium. The glomerulus has three distinct ECMs, although they all have BM constituents as their major matrix types. The Bowman’s capsule has a double BM matrix, while the mesangial cells are surrounded by another pericellular matrix. The third matrix is that of capillary loop. These highly specialised matrices are composed of type IV collagen, laminin, HSPG, fibronectin and chondroitin sulphate proteoglycan. The composition of each matrix helps to determine the physical, mechanical, and functional properties of the glomerulus. Laminin is involved in cell attachment within the glomerular BM (GBM). Heparan sulphate proteoglycans is essential component of the GBM maintaining negative charge necessary to prevent negative charged molecule filtration, which means prevention of loss of protein in urine. The two most abundant mesangial structural proteins are type IV collagen and laminin. It is different from the interstitium ECM having less collagen type I and III. However mesangial cells can produce collagen types I, III, IV, fibronectin, and laminin and other components of the mesangial matrix. Moreover, it is likely that the mesangial cells also regulate the turnover of the constituent components of the matrix. Six different types of collagen IV α chains have been identified in the glomerulus. Glomerular ECM components are synthesized mainly by the podocytes, endothelial cells, resident fibroblasts and to lesser extent by mesangial cells. Glomerular epithelial cells can also produce collagen types I, III, and IV, fibronectin, and laminin, while glomerular endothelial cells produce collagen type IV. The kidney interstitial ECM consists of the tubular basement membrane (collagen IV, laminin, and nidogen). While the interstitial proteins is composed mainly of collagens type I, III, V, VII, XV, fibronectin, and proteoglycans, produced by tubular epithelial cells and interstitial fibroblasts. Most of the kidney ECM components (collagens, fibronectins, laminins, elastins, etc.) are synthesized intra-cellularly and passed extracellularly in various stages of completion to be deposited into the matrix. However it has been shown that kidney cells like mesangial cells and fibroblasts in cultures are capable of producing ECM components which they would not normally produce. Subsequently the production of type I and III collagens by the mesangial cells in culture suggests they could be the source of interstitial collagens seen within the glomerulus in progressive kidney scarring. Remodelling of the kidney ECM is an important physiological feature of normal growth and development. There is a tight balance between kidney ECM synthesis and degradation. Changes in either of these dynamic parameters will potentially result in ECM deposition and accumulation within the glomerulus and the tubulo-interstitium compartments. It is generally believed that excessive ECM deposition seen in kidney scarring is the result of both over production of ECM components and the lack of their clearance.

**THE MMPs**

MMPs, is a group of zinc endopeptidases secreted by a variety of cell types including the kidney cells, MMPs play a central role in ECM breakdown in various kidney diseases. MMPs activity is tightly controlled by a specific class of natural inhibitors known as tissue inhibitors of metalloproteinases (TIMPs). MMPs, is a big family of 28 members (MMP1–28) involved in remodeling of
MMPs have a leader sequence, propeptide domain, and a catalytic domain with the zinc-binding site (Zn). The majority of family members have a hinge and hemopexin-like domain. Other domains are represented in one or more family members, such as the fibronectin-like domain, collagen type V—like domain, and transmembrane domain.

ECM through degrading and turning over all of its components. MMPs have been viewed as bulldozers, destroying ECM and promoting tissues remodeling in health and tissue destruction in pathological diseases. MMPs are zinc and calcium-dependent enzymes that are tightly regulated and expressed constitutively at low levels in most cell types and tissues. Their expression can be induced and up regulated during active normal and abnormal tissue remodeling processes, such as embryonic development, tissue repair, inflammation, tumour invasion and metastasis. Each MMP member has the potential to degrade at least one component of the ECM, with maximal activity around neutral pH.12) MMPs have been classified based on their substrate specificity into different subclasses which include the interstitial collagenases (MMP-1, MMP-8, MMP-13), stromelysins (MMP-3, MMP-7, MMP-10, MMP-11), gelatinases (MMP-2, and MMP-9), and membrane type MMP (MT-MMP) (MMP-14, MMP-15, MMP-16, MMP-17, MMP24, and MMP-25) (Table 1).3,13] Most MMPs are secreted; however The MT-MMPs display transmembrane domains and are expressed on the cell surfaces. MMPs are multidomain enzymes and they are grouped according to their domain structure as is shown in Fig. 1. All MMPs are synthesized as inactive preproenzymes. The “pre” domain is an N-terminal signal sequence which directs MMPs synthesis to the endoplasmic reticulum and gets removed as the proenzyme is secreted from the cell. The pro-domain also serves to keep the enzyme minimally active until its activity is required, by serving as internal MMPs inhibitor. Cleavage of the pro-domain leads to a conformational change in MMPs and they become active.14] Their central catalytic domain contains amino acid residues that bind a central zinc ion and 2–3 calcium ions, both are essential for stability and activation. The purpose of the propeptide cleavage is to expose this zinc ion which is essential for MMPs activation, and explains the word ‘metallo’ in their name. Most of the MMPs except MMP-7, and MMP-26, have a disulfide-bonded carboxy-terminal portion (hemopexin domain region) which is connected to the catalytic domain by a hinge, and is thought to mediate additional protein–protein interactions with substrates (substrate specificity), and interaction with TIMPs.15] The hinge region, in turn, varies in length and composition among the various MMPs and also influences substrate specificity.16,17] Gelatinases (MMP-2 and MMP-9) are characterized by having three cysteine-rich repeats within their catalytic domain, which are believed to be fibronectin-type II like domain. These inserts are required to bind and cleave collagens.14] Some MMPs like MMP-9 has a type V collagen (Col V) domain which has a role in modulating protein interactions important in substrate recognition. The MT-MMPs with the exception of MMP-17 and MMP-25, have a single-pass transmembrane domain and a short cytoplasmic C-terminal tail (about 20 amino acids). The cytoplasmic domain of MT-MMPs may have a role in the regulation of their activity on the cell surface. On the other hand MT-MMP-17 and MT-MMP-25 have a glycosyl-phosphatidyl inositol (GPI)-anchored domains, which are important in cell surface localization and activation.18] Other domains like the furin domain helps in providing an alternative cleavage site for MMP activation. Ten members of MMPs are expressed in the kidney; MMP-1, -2, -3, -9, -13, -14, -24, -25, -27, -28, and six members have been extensively studied in the kidney; MMP-1, -2, -3, -9, -13, and MT-1-MMP.19]
Table 1. The MMPs

<table>
<thead>
<tr>
<th>Enzymes</th>
<th>MMP number</th>
<th>Matrix substrates</th>
<th>Producing kidney cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagenases</td>
<td>MMP-1 (55 kD)</td>
<td>Collagens types I, II, III, VII, VIII, X, gelatin, and proteoglycan, (degrading collagen III&gt;1)</td>
<td>Mesangial cell, endothelial cell, tubulo-epithelial cell, fibroblasts, macrophage</td>
</tr>
<tr>
<td></td>
<td>MMP-2 (75 kD)</td>
<td>Collagens types I, II, III (degrading collagen type I&gt;III)</td>
<td>Neutrophils</td>
</tr>
<tr>
<td></td>
<td>MMP-3 (72 kD)</td>
<td>Collagen type I, II, III</td>
<td>Fibroblasts</td>
</tr>
<tr>
<td></td>
<td>MMP-9 (92 kD)</td>
<td>Collagen types III, IV, V, gelatin, proteoglycans and elastin</td>
<td>Same as MMP-2</td>
</tr>
<tr>
<td></td>
<td>MMP-10 (82 kD)</td>
<td>Collagen types III, IV, V, gelatin, proteoglycans, elastin, and entactin</td>
<td>Mesangial, tubulo-epithelial cells, fibroblasts.</td>
</tr>
<tr>
<td></td>
<td>MMP-11 (51 kD)</td>
<td>Collagen types IV, fibronectin, gelatin, elastin, and entactin</td>
<td>Fibroblasts</td>
</tr>
<tr>
<td></td>
<td>MMP-13 (57 kD)</td>
<td>Collagen types IV, VII, IX, X, elastin, proteoglycan, gelatin, fibronectin, lamnin.</td>
<td>Unkown</td>
</tr>
<tr>
<td></td>
<td>MMP-14 (63 kD)</td>
<td>Collagen types I, II, III, gelatin, fibronectin, laminin, proteoglycan, collagen I, II, III, ProMMP2, ProMMP13</td>
<td>Mesangial, and fibroblasts</td>
</tr>
<tr>
<td></td>
<td>MMP-15 (72 kD)</td>
<td>Gelatin, fibronectin, tenasin, nidogen, aggrecan, percan.</td>
<td>Unkown</td>
</tr>
<tr>
<td></td>
<td>MMP-16 (64 kD)</td>
<td>Collagen III, gelatin, fibronectin,</td>
<td>Unkown</td>
</tr>
<tr>
<td></td>
<td>MMP-17</td>
<td>Gelatin, ProMMP2</td>
<td>ProMMP2</td>
</tr>
<tr>
<td></td>
<td>MMP-18</td>
<td>Gelatin, ProMMP2</td>
<td>Unkown</td>
</tr>
<tr>
<td></td>
<td>MMP-24 (53 kD)</td>
<td>Elastin, fibronectin, gelatin, ProMMP2</td>
<td>Unkown</td>
</tr>
<tr>
<td></td>
<td>MMP-25 (63 kD)</td>
<td>Gelatin, ProMMP2</td>
<td>Unkown</td>
</tr>
</tbody>
</table>

MMPs ACTIVATION AND REGULATION

Activation of MMPs is mainly occurring in the pericellular environment away from natural inhibitors. The activation process occurs by use of a mechanism called the cysteine switch. MMPs are folded by the binding of amino acid 73 (cysteine) via a disulphide bond to the zinc molecule in the active site thus blocking the catalytic site. To activate the switch a water molecule must be allowed access to the zinc molecule, leading to dissociation of the thiol-bearing propeptide from the active zinc atom. Once the link between the cysteine and zinc is broken the protein undergoes a conformational change and the MMPs undergo auto proteolysis to release the propeptide and gain full activity. The opposite happens when cysteine is “on” the zinc, the activity of the enzyme is “off.” Thus, the dissociation of cysteine from the zinc atom is viewed as the “switch” that leads to activation. It is believed that such activation (The cysteine-switch mechanism) occurs in the pericellular and extracellular environment, and is applicable to all members of MMPs. There are other pathways of in vivo activation where MMPs are activated by other active MMPs, like the extra cellular activation of proMMP-9 by active MMP-2, MMP-3 and MMP-13. proMMP-13 also can be activated by active MMP-2 and MMP-3, also MMP-3 activates proMMP-1. The membrane type-MMPs can also activate secreted MMPs like the activation of proMMP-2 by MT1-MMP in a pathway which is TIMP-2 dependent.
Table 2. TIMPs

<table>
<thead>
<tr>
<th>TIMPs</th>
<th>Inhibitory effect</th>
<th>Producing kidney cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIMP-1 (28 kD)</td>
<td>All the latent proMMPs and active MMPs. Does not inhibit MMP-14, -16, or -24. Poor inhibitor of MMP-19 and a number of MT-MMPs</td>
<td>All mesenchymal tissues including intrinsic glomerular cells (mesangial cells and capillary endothelium), macrophages, and fibroblasts.</td>
</tr>
<tr>
<td>TIMP-2 (23 kD)</td>
<td>All the latent proMMPs and active MMPs.</td>
<td>Mesangial, glomerular epithelial cells</td>
</tr>
<tr>
<td>TIMP-3 (21 kD)</td>
<td>All the latent proMMPs and active MMPs. Inhibits A Disintegrin and a Metalloproteinase (ADAMs), as well as the matrix-associated ADAM with a thrombospondin-like motif (ADAM-TS)</td>
<td>Fibroblasts</td>
</tr>
<tr>
<td>TIMP-4 (22 kD)</td>
<td>MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

TIMPs

TIMPs are multifunctional proteins and the major endogenous regulators of MMPs activities in the tissue. Four distinct TIMPs molecules (21–30 kDa, TIMPs-1 to 4) have been isolated, cloned, sequenced, and characterised from several species (Table 2). All TIMPs inhibit active MMPs with relatively low selectivity, forming tight non-covalent 1:1 complexes with the activated catalytic zinc in the MMPs. Details of the MMP-TIMP interaction were a mystery for years until the crystal structure of the complex formed between TIMP-1 and the catalytic domain of MMP-3 was discovered by Gomis-Ruth et al. (1997). Most of the intermolecular contacts between these two proteins are restricted to the first five amino-terminal residues of TIMP-1, which binds to the active site in a substrate-like manner. Tissue inhibitors of metalloproteinases are not actually changed or modified by their interaction. The concept exists that a balance between the level of active MMPs and their inhibitors regulates proteolytic activity. The TIMPs have six disulphide bonds and comprise a three-loop N-terminal domain and an interacting three-loop C-subdomain. The TIMPs are secreted proteins, but may be found at the cell surface in association with MT-MMPs; for example,
TIMP-2, TIMP-3 and TIMP-4 could bind MMP-14. Uniquely, TIMP-3 is sequestered to the ECM by binding to heparan-sulphate-containing proteoglycans and possibly chondroitin-sulphate-containing proteoglycans.  

**MMPs AND THEIR INHIBITORS IN THE DEVELOPING KIDNEY**

Kidney development is characterized by a high rate of ECM turnover. During renal development, a constant remodeling of ECM is required to allow invasion and branching of the ureteric bud in the metanephric mesenchyme. MMPs play an important role in epithelium—mesenchyme interactions in renal development and the determination of nephron number in the developing kidney. MMP-2 mRNA expression is limited to the mesenchyme. However, MMP-2 protein has been found in immature nephron structures undergoing epithelial differentiation, where it co-localizes with MT-1-MMP, TIMP-2, and TIMP-3. This has given rise to the hypothesis that the interaction between MMP-2, MT-1-MMP, and TIMP-2 may be crucial for the interaction between mesenchyme and epithelium, facilitating branching of the developing ureteric bud. Inhibition of MMP-2 by TIMP-2 reduces significantly the number of branches in the rat metanephros. Branching morphogenesis of the ureteric bud requires functional MMP9 activity, anti-MMP-9 antibody preventing ureteric bud branching. Also other MMPs, such as MMP-1, have been shown to play a role in branching morphogenesis.

**MMPs AND THEIR INHIBITORS IN EXPERIMENTAL CKD**

Involvement of the MMPs/TIMPs system has been implicated in kidney tubulo-interstitial fibrosis and glomerulosclerosis for more than two decades. The imbalance in the MMPs/TIMPs system with reduced MMPs activity, and the up regulation of the natural inhibitors TIMPs was very popular theory, where extensive ECM accumulation leads to progression of kidney scarring. Many studies have measured MMPs and or their activity in experimental models of inflammatory and non inflammatory glomerular disease, and in progressive kidney scarring. Down regulation of MMPs has been associated with progression in hypertensive glomerulosclerosis, heroin nephropathy, sex-related changes in the aging kidney, Unilateral Ureteric Obstruction (UUO), and renal ligation. In the UUO rat model it was shown that both the gelatinolytic and collagenolytic activity were reduced in the evolution of interstitial kidney fibrosis, and that was mainly due to increase TIMP-1 protein and lack of activation of latent forms of MMP-1 and MMP-9. Johnson et al. (2002) previously measured the MMPs activity in the 5/6 subtotal nephrectomized (SNx) rat, a model of CKD which develops proteinuria, hypertension, and increased matrix protein deposition leading to decline in kidney function. Johnson and colleagues reported raised TIMP-1 and TIMP-3 mRNA at day 90 post SNx in comparison to normal control. The overall collagenase activity was reduced in the SNx homogenate using collagen I and IV substrates. However, there was increase in mRNA for MMP-1 and MMP-2, indicating an inhibitory effect by TIMPs rather than reduced MMPs transcription or activation. Most of the studies which measured ECM activity were homogenate based assay and conclusions were drawn on an overall activity rather than in situ localized activity or immunohistochemical localization of MMPs or TIMPs members. Others have shown various different expressions of TIMPs/MMPs members in various experimental kidney models. MMP-1 immunostaining was shown to be upregulated in the cytoplasm of the tubular epithelial cells in the cisplatin nephropathy rat model of kidney scarring. However late as the scarring progressed and collagen III became deposited there was decreased in MMP-1 levels intracellularly. In the anti-Thy 1.1 nephritis, rat model of mesangial proliferative glomerulonephritis, an increase in proliferation of mesangial cells is associated with massive expression of MMP-2 and accumulation of extracellular matrix proteins, and that was observed within foci of proliferating mesangial cells and injured basement membrane. These inflammatory features were shown to be attenuated by a synthetic MMPs inhibitor. It was shown that TGF-β1 has a role in inducing MMP-2 in the same model and in other models of induced nephritis where both MMP-2 and TGF-β1 mRNA were elevated. MMP-2 mRNA was also increased initially then fell progressively in renal ischaemia-reperfusion injury rat model in association with increase mRNA of TIMP1, and TGF-β1. In the rat streptozotocin model of diabetic nephropathy it was described...
that MMP-2 immunostain decreased intracellular in the glomeruli (epithelial and mesangial cells). Also in the glomerulonephritis-hereditary nephritic mice, lower activity levels of MMP-1, -2, and -9 but not MMP-3 was shown. In another model of experimental scarring induced by nephrectomy, MMP-1, -3 mRNA levels were shown to increase 3 folds within the kidney cortex 24 hr following unilateral nephrectomy, and then gradually decreased to the control level after 7 days. In contrast the expression of MMP-2 and MMP-9 which remained unchanged in the same model, in association with significant increase in TIMP-1 mRNA levels within the renal cortex 12 hr following nephrectomy. MMP-9 was shown to decrease by immunohistochemistry during progressive glomerulosclerosis in the obese Zucker rat model of insulin resistance and hyperlipidaemia in association, there was decreased gelatinolytic activity with upregulation of TIMP-1 protein levels. MMP-9 has been up regulated in the glomeruli of proteinuric rat model with passive Heymann nephritis, also MMP-9 immunohistochemical staining was significantly higher in the cytoplasm of tubular cells of the acute pyelonephritis model of renal scarring. TIMP-1 was thought to be a key player in ECM deposition associated with CKD, TIMP-1 was found to be significantly elevated in several experimental models of kidney scarring like, protein-overload proteinuria rat model, hypercholesterolaemia-induced renal disease, obstructive uropathy, anti tubular basement membrane antibody nephritis, murine lupus nephritis, polycystic kidney disease, cyclosporine nephrotoxicity, Heymann nephritis, and the acute pyelonephritis model of kidney scarring. However, the importance of TIMP-1 was questioned by Eddy and colleagues who showed in an experimental model of bovine serum albumin (BSA)-induced overload proteinuria in TIMP-1 knockout mice that genetic deficiency of TIMP-1 does not appear to protect from developing severe interstitial fibrosis, but that was explained by the high renal constitutive levels of TIMP-2 and/or TIMP-3. We have previously shown MMPs activity in the remnant kidney model to drop significantly in progressive kidney scarring. Using in situ zymography, were able to localize MMPs activity within the tubules in normal rat kidney which was inhibited by adding MMPs specific inhibitor. MMPs activity dropped significantly in the tubules in progressive scarring associated with increase in tubular TIMP-2 by immunohistochemistry. The tubulo-interstitial forms the main bulk of the kidney mass, therefore the overall activity was reduced accordingly. However there was unexpected increase in the glomerular MMPs activity associated with increase in glomerular MMP-1 by immunohistochemistry. These MMPs changes were occurring intracellular and not extracellular. Examination of the literature reveals several studies that have reported predominantly intracellular location of MMPs or TIMPs in experimental CKD.

MMPs AND THEIR INHIBITORS IN HUMAN KIDNEY DISEASE

There are limited number of reports of MMPs/TIMPs expression in human kidney disease. Human kidney biopsies with diabetic nephropathy showed expression of MMP-3, and TIMP-1 mRNA levels were associated with matrix accumulation characteristic of progressive diabetic nephropathy. In addition, MMP-2 mRNA expression was found to be low in glomeruli of non insulin dependant diabetic patients, suggesting that MMPs may play a pivotal role in matrix accumulation in diabetic nephropathy. In situ hybridization on renal biopsy specimens from patients with IgA nephropathy showed MMP-3, and TIMP-1 mRNA expression in glomerular cells, and tubular epithelial cells, was upregulated in association with progression of the disease. However MMP-9 was significantly increased in mesangial proliferative glomeruli and interstitial vascular walls of IgA nephropathy patients, but markedly decreased in sclerotic glomeruli, and not changed in the tubules. It was reported that, in human adult polycystic kidney disease (ADPKD), increased levels of MMP-2 and -9 and stromelysin were localized to tubular cells, with the greatest amounts in the collecting duct epithelia. The expression of glomerular and interstitial MMP-2, -3, -9 and TIMP-1 is increased in active ANCA-associated glomerulonephritis and was shown to correlate with inflammatory activity. MMP-9 was thought to play important role in abnormal mesangial proliferative changes in human GN; glomerular MMP-9 immunostaining increased in parallel with levels of mesangial proliferative changes in IgA nephritis, Henoch–Shönlein nephritis, non-IgA mesangial proliferative GN and in lupus nephritis GN. Also increased gelatinolytic glomerular MMP-9 activ-
ity was observed in nephritic glomeruli with IgA nephritis, lupus nephritis and DN.72) In chronic allograft nephropathy (CAN), elevated serum proMMP-2 and proMMP-3 levels were shown to reflect the changes in glomerular and interstitial extracellular matrix in chronic transplant nephropathy, suggesting that they could play a role in the pathogenesis of CAN.73–75) Also in acute renal allograft rejection that they could play a role in the pathogenesis matrix in chronic transplant nephropathy, suggesting changes in glomerular and interstitial extracellular

2a and proMMP-3 levels were shown to reflect the glomerulosclerosis.

at best prove ineffective and at worst accelerate TIMPs strategies to combat renal scarring may consequently the development of MMPs induction/anti-
tubulo-interstitial scarring remains unclear. Subsequently the exact contribution of elevated TIMPs, MMPs activity in glomerulosclerosis, and place. Hence the exact contribution of elevated

plex pro enzyme/natural inhibitor system being in

were significantly reduced in comparison to ele-
vated TIMP-2, and -3 (unpublished data).

CONCLUSION

The involvement of the MMPs/TIMPs system in the kidney is so extensive starting from development, and has obvious role in progressive glomerulosclerosis and tubulo-interstitial fibrosis. However many interacting factors are also involved in the kidney ECM turnover, and there is no consistency in the literature regarding MMPs/TIMPs expression in various progressive CKD pathology. There are limitations of drawing conclusions based solely on mRNA and antigen measurements with such a complex pro enzyme/natural inhibitor system being in place. Hence the exact contribution of elevated TIMPs, MMPs activity in glomerulosclerosis, and tubulo-interstitial scarring remains unclear. Subsequently the development of MMPs induction/anti-TIMPs strategies to combat renal scarring may at best prove ineffective and at worst accelerate glomerulosclerosis.

REFERENCES


metallopeinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. *FEBS Lett.*, **480**, 142–146.


